All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
MRD Symposium
MRD Symposium
How does MRD impact outcome of stem cell transplantation in AML, now and in the future?
At the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation, the AML Hub will hold a Satellite Symposium on the impact of measurable residual disease (MRD) on stem cell transplantation (SCT) outcome in patients with acute myeloid leukemia.
|||